Cotreatment with Vorinostat Enhances Activity of MK-0457 (VX-680) against Acute and Chronic Myelogenous Leukemia Cells

• Published in: Clinical cancer research Vol. 14; no. 19; pp. 6106 - 6115
• Main Authors: FISKUS, Warren, YONGCHAO WANG, USTUN, Celalettin, JILLELLA, Anand, BUSER, Carolyn A, PEIPER, Stephen, BHALLA, Kapil, JOSHI, Rajeshree, RAO, Rekha, YONGHUA YANG, JIANGUANG CHEN, KOLHE, Ravindra, BALUSU, Ramesh, EATON, Kelly, LEE, Pearl
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.10.2008
• Subjects: Animals; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Aurora kinase; Biological and medical sciences; Cell Line, Tumor; Drug Synergism; Fusion Proteins, bcr-abl - metabolism; Hematologic and hematopoietic diseases; Histones - metabolism; HL-60 Cells; Humans; Hydroxamic Acids - administration & dosage; Inhibitor of Apoptosis Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myeloid, Acute - drug therapy; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical sciences; Mice; Microtubule-Associated Proteins - metabolism; MK-0457; Mutation; Neoplasm Proteins - metabolism; Pharmacology. Drug treatments; Piperazines - administration & dosage; Survivin; Vorinostat; Antineoplastic agent; Myeloproliferative syndrome; Histone deacetylase inhibitor; Acute; Vorinostat; Chronic myelogenous leukemia; Malignant hemopathy; Cell; In vitro; Biological activity; Cancer
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-08-0721

Purpose: We determined the effects of vorinostat (suberoylanalide hydroxamic acid) and/or MK-0457 (VX-680), an Aurora kinase inhibitor on the cultured human (HL-60, OCI-AML3, and K562) and primary acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML), as well as on the murine pro-B BaF3 cells with ectopic expression of the unmutated and mutant forms of Bcr-Abl. Experimental Design: Following exposure to MK-0457 and/or vorinostat, apoptosis, loss of viability, as well as activity and levels of Aurora kinase and Bcr-Abl proteins were determined. Results: Treatment with MK-0457 decreased the phosphorylation of Aurora kinase substrates including serine (S)10 on histone H3 and survivin, and led to aberrant mitosis, DNA endoreduplication as well as apoptosis of the cultured human acute leukemia HL-60, OCI-AML3, and K562 cells. Combined treatment with vorinostat and MK-0457 resulted in greater attenuation of Aurora and Bcr-Abl (in K562) kinase activity and levels as well as synergistically induced apoptosis of OCI-AML3, HL-60, and K562 cells. MK-0457 plus vorinostat also induced synergistic apoptosis of BaF3 cells with ectopic overexpression of wild-type or mutant Bcr-Abl. Finally, cotreatment with MK-0457 and vorinostat induced more loss of viability of primary AML and imatinib-refractory CML than treatment with either agent alone, but exhibited minimal toxicity to normal CD34+ progenitor cells. Conclusions: Combined in vitro treatment with MK-0457 and vorinostat is highly active against cultured and primary leukemia cells. These findings merit in vivo testing of the combination against human AML and CML cells, especially against imatinib mesylate–resistant Bcr-AblT315I–expressing CML Cells.